Preclinical and clinical studies in patients with breast, cervical, endometrial, and ovarian cancer treated with PI3K/AKT/mTOR inhibitors could demonstrate a higher response rate in patients with activating PIK3CA mutation than patients without mutation [20–22]. The gene discussed is AKT1; the disease is ovarian carcinoma.